BioSpace News Archive

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences:

Protara Therapeutics, Inc. announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022.

Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the BIO CEO & Investor Conference being held both virtually and in New York, NY on February 6-9, 2023.

Volta Medical today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.

Achieve Life Sciences, Inc. today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference.

Agomab Therapeutics NV announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal -restricted small molecule kinase inhibitor of ALK5, intended for the treatment of Fibrostenosing Crohn’s Disease.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy initiative, in collaboration with Weill Cornell Medicine, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on February 1, 2023 as inducements material to each employee entering into employment with KalVista.